Korea Arlico Pharm

알리코제약 · 260660

Health Care Pharmaceuticals · KOSDAQ

Small-cap

Market cap US$29.8M (₩41.1B)

Overview

Korea Arlico Pharm makes prescription and over-the-counter medicines, tablets, capsules, and other drug formulations, used by patients and dispensed through hospitals and pharmacies in South Korea and exported abroad.

Listed on KOSDAQ, South Korea's small-cap board, it supplies domestic healthcare channels, provides contract manufacturing (producing medicines on behalf of other pharmaceutical companies), and exports finished drugs and health-related products overseas. Its business spans four main lines: domestic drug sales, contract manufacturing, international exports, and medical devices alongside health-functional foods and cosmetics.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025
Revenue · FY2025
US$145.8M
▲ +5.7% YoY
Operating profit · FY2025
US$716.8K
Turned profitable
Net income · FY2025
−US$438.7K
Loss narrowed

Revenue

  • FY2023US$135.6M
  • FY2024US$138M
  • FY2025US$145.8M

Operating profit

  • FY2023US$2.2M
  • FY2024−US$3.7M
  • FY2025US$716.8K

Net income

  • FY2023US$2.2M
  • FY2024−US$3.9M
  • FY2025−US$438.7K

Key ratios (FY2025)

ROE
-0.8%
Debt/Eq
119.7%
Op. margin
0.5%
Net margin
-0.3%
Rev. YoY
▲ +5.7%

Why it matters

The company operates its own central research laboratory, relocated and expanded to Gwangyo, focused on developing improved new drugs and differentiated drug formulations.

Price charts coming soon

Interactive price history isn't here yet. Would you use it?

For informational purposes only. This is not investment advice, a recommendation, or a solicitation to buy or sell any security. Do your own research; any investment decision is your own responsibility.

Data from DART, Korea's official corporate-filing system. Data sourced from official DART filings. Accuracy is not guaranteed. Figures are as of the date shown. As of 2026-06-12 (KST). · FX: 1 USD ≈ ₩1,380 (2026-06-01).

Company summaries are generated and may contain errors; financial figures are mapped directly from official filings.